TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY

Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...

Descripción completa

Detalles Bibliográficos
Autores principales:	E N Aleksandrova, E Yu Panasyuk, A S Avdeyeva, A A Novikov, G V Lukina, M V Cherkasova, N V Klimova, E L Nasonov
Formato:	Artículo
Lenguaje:	Russian
Publicado:	IMA PRESS LLC 2011-06-01
Colección:	Научно-практическая ревматология
Materias:	rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies
Acceso en línea:	https://rsp.mediar-press.net/rsp/article/view/705

Ejemplares similares

Impact of tocilizumab therapy on immunological parameters in patients with rheumatoid arthritis
por: Anastasia Sergeyevna Avdeyeva, et al.
Publicado: (2012-06-01)

Bone destruction in rheumatoid arthritis: role of autoantibodies
por: Anastasia Sergeyevna Avdeyeva, et al.
Publicado: (2013-06-01)

THE CLINICAL AND IMMUNOLOGICAL EFFECTS OF ANTI-B-CELL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
por: Elena Nikolayevna Aleksandrova, et al.
Publicado: (2012-02-01)

DIAGNOSTIC MARKERS AND CYTOKINE PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING DMARDS
por: Maria Sergeevna Voronina, et al.
Publicado: (2012-10-01)

Anti-modified citrullinated vimentin antibody: a novel biomarker associated with cardiac systolic dysfunction in patients with rheumatoid arthritis
por: Somayye Norouzi, et al.
Publicado: (2020-08-01)

New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)
por: Evgeniy L'vovich Nasonov, et al.
Publicado: (2010-05-01)

Correlation between anti-mutated citrullinated vimentin and bone turnover markers (CTX-1 and P1NP) in patients with rheumatoid arthritis in remission and low-disease activity
por: Tulus Widiyanto, et al.
Publicado: (2022-08-01)

Methotrexate-induced changes in the concentration of antibodies to modified citrulnated vimentin in blood serum of patients with rheumatoid arthritis
por: Natal'ya Petrovna Shilkina, et al.
Publicado: (2011-05-01)

Serum sirtuin-1 a potential marker in the diagnosis of rheumatoid arthritis
por: Liming Tan, et al.
Publicado: (2023-12-01)

Specificity of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis
por: Nicole H. Trier, et al.
Publicado: (2019-06-01)

Assessment of the Correlation between Disease Activity and Serum Biomarker Anti-MCV and IL6 in Iraqi Patients with Rheumatoid Arthritis
por: Dania A. Ali, et al.
Publicado: (2024-10-01)

Rheumatoid factor and antibodies against cyclic citrullinated peptide in patients without rheumatoid arthritis
por: N. V. Bunchuk
Publicado: (2023-01-01)

Antibodies to cyclic citrullinized peptide in rheumatoid arthritis
por: E N Aleksandrova, et al.
Publicado: (2004-12-01)

Epitope Specificity of Anti-Citrullinated Protein Antibodies
por: Nicole H. Trier, et al.
Publicado: (2017-03-01)

Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis
por: Akio Umemoto, et al.
Publicado: (2023-02-01)

The roles of anti-citrullinated protein antibodies in the immunopathogenesis of rheumatoid arthritis
por: Hui-Chun Yu, et al.
Publicado: (2019-01-01)

Specificity of Anti-Citrullinated Protein Antibodies to Citrullinated α-Enolase Peptides as a Function of Epitope Structure and Composition
por: Ilaria Fanelli, et al.
Publicado: (2021-07-01)

Antibodies against citrullinated proteins in relation to periodontitis with or without rheumatoid arthritis: a cross-sectional study
por: Pit Hui Lew, et al.
Publicado: (2021-07-01)

Different clinical relevance of anti-citrullinated proteins antibodies in RA patients
por: A. S. Avdeeva, et al.
Publicado: (2022-05-01)

INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
por: E. L. Nasonov, et al.
Publicado: (2018-01-01)

Tocilizumab (Actemra)
por: Martin Sheppard, et al.
Publicado: (2017-09-01)

Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production
por: Hisakata Yamada, et al.
Publicado: (2020-04-01)

Evaluation of anti-mutated citrullinated vimentin antibodies, anti-cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis in comparison with other rheumatic diseases; a nephrology point of view
por: Alireza Sadeghi, et al.
Publicado: (2017-04-01)

Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels
por: Diana Castillo-Martínez, et al.
Publicado: (2017-02-01)

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement
por: S.L.E. Ribeiro, et al.
Publicado: (2008-11-01)

RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN PATIENTS WITH PSORIATIC ARTHRITIS
por: V. V. Badokin, et al.
Publicado: (2011-06-01)

When Autoantibodies Are Missing: The Challenge of Seronegative Rheumatoid Arthritis
por: Marino Paroli, et al.
Publicado: (2023-10-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies (anti-CCP) in patients with rheumatoid arthritis
por: Damjanovska Ljubinka, et al.
Publicado: (2007-01-01)

INVESTIGATION OF CANDIDATE GENE POLYMORPHISMS IN AN IMMUNE RESPONSE AS MARKERS FOR THE RISK OF DEVELOPING RHEUMATOID ARTHRITIS AND PRODUCING AUTOANTIBODIES
por: I. A. Guseva, et al.
Publicado: (2016-03-01)

THE 2016 EULAR GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EARLY ARTHRITIS
por: E. L. Nasonov
Publicado: (2017-04-01)

The clinical aspect of overweight on rheumatoid arthritis and disease activity
por: Haitham Ahmed, et al.
Publicado: (2019-06-01)

Evaluation of a new biomarker 14-3-3 Eta protein in diagnosis of rheumatoid arthritis
por: Lakshmi Deepika Yarlagadda, et al.
Publicado: (2020-01-01)

Asthma and elevation of anti-citrullinated protein antibodies prior to the onset of rheumatoid arthritis
por: Alessandra Zaccardelli, et al.
Publicado: (2019-11-01)

Cerebrovascular reactivity depending on rheumatoid factor and anticitrullinated protein antibody positivity in hypertensive patients with rheumatoid arthritis
por: N. V. Rebrova, et al.
Publicado: (2022-07-01)

RAPID EFFECT OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS
por: E Yu Panasyuk, et al.
Publicado: (2011-08-01)

THE CLINICAL AND DIAGNOSTIC VALUE OF ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODIES IN EARLY JUVENILEARTHRITIS
por: S O Salugina, et al.
Publicado: (2009-06-01)

Multicenter, observational clinical study of abatacept in Japanese patients with rheumatoid arthritis
por: Noriyoshi Ogawa, et al.
Publicado: (2019-01-01)

The diagnostic value of anti-cyclic citrullinated peptide antibodies, adenosine deaminase activity and other potential biomarkers for predicting and monitoring rheumatoid arthritis
por: Mehanović-Nikolić Jasminka, et al.
Publicado: (2008-01-01)

An assessment of anti-citrullinated protein antibody in systemically healthy individuals with or without chronic periodontitis: A case–control study
por: Ankita Rajaram Yadav, et al.
Publicado: (2020-01-01)

DIAGNOSTIC VALUE OF ANTI-PEPTIDYLARGININE DEIMINASE TYPE 4 (PADI-4) AND ANTI- CITRULLINATED PEPTIDE ANTIBODIES (ACCP) IN IRAQI PATIENTS WITH RHEUMATOID ARTHRITIS
por: Hassan J Hasony, et al.
Publicado: (2014-06-01)